DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment.
1,2-Dipalmitoylphosphatidylcholine
/ chemistry
Administration, Inhalation
Animals
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Drug Carriers
/ chemistry
Drug Liberation
Drug Stability
Glycerides
/ chemistry
Lung
/ blood supply
Male
Myocytes, Smooth Muscle
/ drug effects
Nanoparticles
/ chemistry
Particle Size
Pulmonary Arterial Hypertension
/ drug therapy
Pulmonary Artery
/ drug effects
Rats, Sprague-Dawley
Resveratrol
/ administration & dosage
Surface Properties
Lipid nanoparticles
pulmonary arterial hypertension
pulmonary delivery
pulmonary surfactant
resveratrol
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
4
2
2021
Statut:
ppublish
Résumé
In this study, we investigated the feasibility of dipalmitoylphosphatidylcholine-coated lipid nanoparticles (DPPC-LNs) as a carrier for preferential accumulation into lungs of Resveratrol (Res), a potentially promising drug for the treatment of pulmonary arterial hypertension (PAH). Res-loaded DPPC-LNs were prepared following a thin film hydration-ultrasonic dispersion technique using glyceryl monostearate as lipid core. DPPC can reduce the interactions between nanoparticles and pulmonary surfactant. The optimal formulation was prepared and characterized for physicochemical properties, storage stability and
Identifiants
pubmed: 32397765
doi: 10.1080/10717544.2020.1760962
pmc: PMC7269040
doi:
Substances chimiques
Drug Carriers
0
Glycerides
0
glyceryl monostearate
230OU9XXE4
1,2-Dipalmitoylphosphatidylcholine
2644-64-6
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
736-744Références
Pharmazie. 2010 Aug;65(8):585-7
pubmed: 20824958
Circ Res. 2011 Sep 2;109(6):639-48
pubmed: 21778425
IUBMB Life. 2011 Aug;63(8):607-12
pubmed: 21721102
Arch Toxicol. 2017 Mar;91(3):1261-1278
pubmed: 27358235
Trends Mol Med. 2017 Jan;23(1):31-45
pubmed: 27989641
Biophys J. 2014 Jan 7;106(1):289-98
pubmed: 24411261
Nat Rev Cardiol. 2018 Dec;15(12):770-779
pubmed: 30367136
J Exp Clin Cancer Res. 2016 Jul 22;35(1):118
pubmed: 27448598
Rheumatol Int. 2012 Jan;32(1):151-7
pubmed: 20697895
J Microencapsul. 2016 Dec;33(8):735-742
pubmed: 27841060
J Biomed Nanotechnol. 2017 Jan;13(1):99-09
pubmed: 29373003
J Control Release. 2012 Mar 10;158(2):182-93
pubmed: 21978644
Int J Pharm. 2012 Jul 1;430(1-2):216-27
pubmed: 22465548
Cell Physiol Biochem. 2017;42(1):55-67
pubmed: 28494457
Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1694-9
pubmed: 16973825
Circulation. 2006 Sep 26;114(13):1417-31
pubmed: 17000921
Circulation. 2014 Dec 9;130(24):2189-208
pubmed: 25602947
Colloids Surf B Biointerfaces. 2014 Jun 1;118:234-42
pubmed: 24816150
N Engl J Med. 1994 May 19;330(20):1431-8
pubmed: 8159199
Drug Metab Dispos. 2004 Dec;32(12):1377-82
pubmed: 15333514
Expert Opin Drug Deliv. 2015 Apr;12(4):583-99
pubmed: 25391992
Trends Mol Med. 2017 Sep;23(9):786-798
pubmed: 28789830
Biomed Res Int. 2015;2015:762349
pubmed: 26273643
Int J Nanomedicine. 2012;7:5733-44
pubmed: 23166438
Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2417-24
pubmed: 17220179
Int J Pharm. 2011 May 16;409(1-2):156-63
pubmed: 21356284
J Control Release. 2018 Dec 10;291:116-126
pubmed: 30321577
Lancet Respir Med. 2016 Apr;4(4):306-22
pubmed: 26975810
Curr Med Chem. 2012;19(11):1663-81
pubmed: 22257059